Advertisement

ADVERTISEMENT

Non-Small-Cell Lung Cancer

News
Pralsetinib Efficacy for Patients With Advanced RET Fusion-Positive NSCLC
06/22/2023

Amber Denham

Amber Denham
In a phase 1/2 study, pralsetinib demonstrated lasting clinical activity and a well-tolerated safety profile among patients with RET fusion-positive non-small cell lung cancer.
In a phase 1/2 study, pralsetinib demonstrated lasting clinical activity and a well-tolerated safety profile among patients with RET fusion-positive non-small cell lung cancer.
In a phase 1/2 study,...
06/22/2023
Oncology
News
Selpercatinib Superior to Prior Systemic Therapy in RET-Positive NSCLC
06/22/2021
Patients with RET-positive NSCLC who received selpercatinib therapy had a better overall response than those who received prior systemic therapy, according to findings from the phase 1/2 LIBRETTO-001 trial.
Patients with RET-positive NSCLC who received selpercatinib therapy had a better overall response than those who received prior systemic therapy, according to findings from the phase 1/2 LIBRETTO-001 trial.
Patients with RET-positive NSCLC...
06/22/2021
Oncology
Profile
Videos
Dr Baik Discusses Patritumab Deruxtecan for EGFR+ NSCLC
06/16/2021
Christina Baik, MD, MPH, discusses the efficacy and safety of patritumab deruxtecan therapy for patients with EGFR inhibitor-resistant EGFR+ NSCLC.
Christina Baik, MD, MPH, discusses the efficacy and safety of patritumab deruxtecan therapy for patients with EGFR inhibitor-resistant EGFR+ NSCLC.
Christina Baik, MD, MPH,...
06/16/2021
Oncology
News
Sotorasib Safe, Effective for KRAS p.G12C-mutated NSCLC
06/10/2021
Sotorasib therapy demonstrated durable efficacy with manageable safety for previously treated KRAS p.G12C-mutated NSCLC.
Sotorasib therapy demonstrated durable efficacy with manageable safety for previously treated KRAS p.G12C-mutated NSCLC.
Sotorasib therapy demonstrated...
06/10/2021
Oncology
Videos
Dr Spira Talks Amivantamab Plus Lazertinib for Osimertinib-Relapsed, EGFR+ NSCLC
06/09/2021
Alexander Spira, MD, PhD, FACP, discusses the use of amivantamab in combination with lazertinib for the treatment of chemo-naïve patients with osimertinib-relapsed, EGFR+ NSCLC.
Alexander Spira, MD, PhD, FACP, discusses the use of amivantamab in combination with lazertinib for the treatment of chemo-naïve patients with osimertinib-relapsed, EGFR+ NSCLC.
Alexander Spira, MD, PhD, FACP,...
06/09/2021
Oncology
Videos
Dr Bruno Highlights Racial Disparities in Testing, Trial Enrollment in NSCLC
06/07/2021
Dr Bruno, MD, discusses the racial disparities in biomarker testing and clinical trial enrollment in patients with NSCLC.
Dr Bruno, MD, discusses the racial disparities in biomarker testing and clinical trial enrollment in patients with NSCLC.
Dr Bruno, MD, discusses the...
06/07/2021
Oncology
Dr Le Shares Promising Data on Poziotinib for NSCLC With EGFR or HER2 Mutations
Videos
Dr Le Shares Promising Data on Poziotinib for NSCLC With EGFR or HER2 Mutations
04/28/2021
Xiuning Le, MD, PhD, discusses results from the ZENITH20 trial, which showed that twice daily poziotinib improved AEs and retained anti-tumour activity in EGFR+ or HER2+ NSCLC.
Xiuning Le, MD, PhD, discusses results from the ZENITH20 trial, which showed that twice daily poziotinib improved AEs and retained anti-tumour activity in EGFR+ or HER2+ NSCLC.
Xiuning Le, MD, PhD, discusses...
04/28/2021
Oncology
Conference Insider
Pembrolizumab Plus Chemo Promising for Treatment of NSCLC
03/24/2021
In patients with advanced NSCLC that lack targetable mutations, pembrolizumab combined with chemo has shown promising results, according to research presented at the NCCN annual conference.
In patients with advanced NSCLC that lack targetable mutations, pembrolizumab combined with chemo has shown promising results, according to research presented at the NCCN annual conference.
In patients with advanced NSCLC...
03/24/2021
Oncology
Conference Insider
Improved Survival With Treatment Guided by Biomarker Testing for NSCLC
03/19/2021
Patients with advanced/metastatic NSCLC have improved survival after treatment guided by biomarker testing, according to research presented at the NCCN Annual Conference.
Patients with advanced/metastatic NSCLC have improved survival after treatment guided by biomarker testing, according to research presented at the NCCN Annual Conference.
Patients with...
03/19/2021
Oncology
News
Angioinhibition in the Management of NSCLC
12/11/2020
Edward B. Garon MD, MS, engaged in a stimulating debate regarding the relevancy of angioinhibition in the management of NSCLC, particularly for EGFR-positive patients, at the virtual 2020 Personalized Therapies in Thoracic Oncology meeting.
Edward B. Garon MD, MS, engaged in a stimulating debate regarding the relevancy of angioinhibition in the management of NSCLC, particularly for EGFR-positive patients, at the virtual 2020 Personalized Therapies in Thoracic Oncology meeting.
Edward B. Garon MD, MS, engaged...
12/11/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

ECS
November 8 ⁠–⁠ November 10
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use